Latest
May
08
Positioning for Success: Navigating China’s C-List and Commercial Catalog for Innovative Medicines
Gain practical tools and insight to navigate China’s C-List and Commercial Catalog—and make informed decisions on product positioning across emerging access pathways.
2 min read
Apr
30
NRDL+ 2025 Annual Executive Debrief: The State of Access for Innovative Medicines in China
This Access360 Executive Briefing lays the groundwork for understanding China’s shift toward value-based pricing, deeper insurance–medicine–care integration, and broader market transformation driven by its national commercial insurance catalog initiatives.
1 min read
Apr
02
China’s Insurance Industry Moves to Standardize Drug Coverage: Draft Commercial A-List Now Open for Feedback
As NHSA pilots C-List reimbursement models, a parallel effort by the Insurance Association of China has produced its first national formulary draft—offering a framework that could define future specialty drug access under Huiminbao and beyond.
3 min read
Mar
05
China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List
Led by the Insurance Association of China, this initiative alongside the NHSA-led Category C Drug List, is reshaping funding pathways, pricing strategies, and market access for innovative medicines.
5 min read
Feb
12
NHSA Fast-Tracks China's First Category C Drug List to Expand Commercial Funding for Innovative Medicines
The launch of the Category C Drug List marks a major milestone in China’s reimbursement landscape for innovative therapies. Its success will hinge on transparent selection criteria, fair pricing strategies, and broad market adoption.
4 min read
Feb
05
Pioneering Value-Based Care in China: A Conversation with Dr. Felix Lee, Co-CEO of The GBA Healthcare Group
This success story emphasizes the importance of aligning healthcare innovation with a nation's infrastructure and social security framework to ensure practical, scalable, and sustainable care delivery and payment models.
15 min read
Jan
02
The Future of Innovative Medicine Pricing and Reimbursement in China: Signals from the 2024 NRDL Negotiations
These developments call for a global pricing strategy rooted in China's evolving reimbursement infrastructure, breaking siloed thinking to balance short-term goals with long-term growth.
9 min read
Dec
04
NHSA Strengthens Control Over Outpatient Spending
Effectively navigating these regulatory changes will have significant and lasting implications for drug manufacturers, particularly in shaping their pricing strategies, reimbursement models, and distribution channel approaches in China.
7 min read
Nov
06
Advances in New Technology Add-On Payments for Innovative Medicine in China’s DRG/DIP Framework
In July, China’s National Healthcare Security Administration introduced the CHS-DRG Grouping Plan (Version 2.0), expanding the number of
5 min read
Oct
15
▶️China's Medical Service Pricing Reform: Impact on Innovative Medical Technology Pricing and Adoption
Stay ahead of value-based approval and pricing trends for medical services and discover strategic growth opportunities to support clinical and commercial strategies for innovative medical technologies in China.
1 min read